Zelira Therapeutics secured nearly US$33 million for its HOPE® 1 autism drug SPV, aiming to progress FDA clinical trials despite fundraising delays and tight cash reserves.
- US$33M raised for HOPE® 1 SPV with Zelira holding 39.7%
- Fundraising delayed but remains committed to closing
- Q3 FY2026 net cash outflow of A$335k, cash at A$28k
- Director loans of A$50,000 convertible at A$0.58
- Progress on diabetic nerve pain drug ZLT-L-007 FDA plans
Fundraising Boosts HOPE® 1 Clinical Push
Zelira Therapeutics (ASX:ZLD) has secured a transformative US$32.98 million fundraising into its HOPE® 1 special purpose vehicle (SPV), valuing the entity at approximately US$66 million post-money. Zelira retains a 39.7% stake in the SPV, equating to a post-money interest valued at US$26.2 million. The capital raise is intended to bankroll the accelerated FDA 505(b)(2) regulatory pathway for HOPE® 1, a cannabinoid-based medicine targeting autism spectrum disorder, including Phelan-McDermid Syndrome.
The fundraising was originally scheduled to close by 31 January 2026 but has been delayed due to factors outside the control of Zelira and its funding partner ThirdGate Capital. Both parties remain committed to closing the transaction and advancing the clinical program. The delay introduces uncertainty around timing, although the company continues to progress preparatory regulatory activities.
Clinical Milestones and Regulatory Strategy
Zelira’s immediate focus is on submitting an Investigational New Drug (IND) application to the FDA, aligned with prior Pre-IND guidance, and initiating the Phase 1 clinical trial; the first formal dosing of HOPE® 1 in humans under FDA oversight. The company is also pursuing Orphan Drug Designation, aiming to leverage incentives for rare disease treatments. This pathway could accelerate regulatory approval and enhance commercial prospects.
The SPV will also complete payment for Zelira’s proprietary Zyraydi technology license, which reformulates HOPE® 1 into a free-flowing powder capsule, reducing manufacturing costs and enhancing competitiveness. Zelira’s Chairman and SPV Executive Chair, Osagie Imasogie, emphasised the partnership with ThirdGate Capital to efficiently navigate the FDA process and accelerate clinical progress.
Financial Position and Operational Cash Flow
Operationally, Zelira reported a net cash outflow of A$335,000 for Q3 FY2026, with cash reserves dwindling to A$28,000 at quarter-end. Key expenses included research and development costs associated with HOPE® 1 trial preparations (A$32,000) and staff costs (A$204,000). Administrative and corporate costs decreased to A$132,000, reflecting payment timing variations.
To bridge short-term funding gaps, Non-Executive Director Tim Slate provided an unsecured A$50,000 loan convertible into shares at A$0.58, pending shareholder approval. This director loan is part of a broader financing strategy that includes other director loans bearing 20% interest per annum.
Pipeline Progress Beyond HOPE® 1
Beyond HOPE® 1, Zelira is advancing its diabetic nerve pain drug candidate ZLT-L-007. Following positive top-line results from an IRB-approved trial demonstrating superior efficacy to the pharmaceutical standard Lyrica®, Zelira is evaluating progression into formal FDA clinical trials. This development could diversify the company’s clinical portfolio and revenue streams.
Zelira’s prescription cannabinoid medicines, including HOPE® formulations, are generating revenue in select US states such as Washington, D.C., Pennsylvania, and Louisiana. The company also plans to commercialise ZENIVOL®, a cannabinoid drug for chronic insomnia, in Germany through its partner Adjupharm GmbH, pending regulatory approval.
Funding and Reporting Outlook
The company intends to lodge its interim financial statements for the six months ended 31 December 2025 shortly after the fundraising closes. This report will offer further clarity on Zelira’s financial position and operational progress. The successful closing of the HOPE® 1 SPV fundraising remains a critical catalyst, underpinning the company’s ability to execute its FDA clinical trial strategy and broader commercial ambitions.
Investors following Zelira’s trajectory will recall the initial fundraising announcement in January 2026, which laid out the US$33 million capital injection to fuel HOPE® 1 trials HOPE 1 FDA Trials. The current update reflects the ongoing complexities of closing such a sizable raise, consistent with the company’s previous capital management challenges R&D Refund Boosts Pipeline.
Bottom Line?
Zelira’s ability to close its HOPE® 1 fundraising and initiate FDA trials will be pivotal amid tight cash reserves and operational burn.
Questions in the middle?
- When will the HOPE® 1 SPV fundraising definitively close?
- How will Zelira manage liquidity until fundraising completion?
- What are the timelines for FDA IND submission and Phase 1 dosing?